Advanced Prostate Cancer

40 Posts | Page(s): Prev 12 3 4 

RE: Advanced Prostate Cancer

by ToddlerFather on Tue Dec 11, 2018 01:03 AM

Quote | Reply

On Dec 11, 2018 12:24 AM thomsor wrote:

If this doesn't work, then we'll be sure to try that.  However, this is really throwing the book at it.   Doing one thing is putting all your eggs in one basket so to speak.  They list 3 of the things he's doing as cancer fighting:  carrot juice, electromagnetic therapy, hawaiian astelin.  The fuoicidan is brown seaweed, the cellect is immune support.  The liver support is essential because the liver has to process the food.  The green drinks are another support.  All I can say is that his psa went from 33 to 19 in 1 1/2 months.  Prior to going to 33, his PSA was 22 for a long time.  They say sugar feeds cancer so he tries to stay away from it.

Except for taking pain medication (opiace), there is no issue in taking LDN and doing everything already being done. Actually, what is usually not suggested by LDN praticioners is exactly getting off your other treatments. That's why one of the indicators that LDN works is from people who start taking LDN, get better, stop taking LDN against medical advice and get worse again. The other is for cases of stand-alone usage LDN. 

Cases like mine, where LDN works standalone, are not as common... but the close proximity between the endocrine cancers make this a possibility against prostate cancer if the other therapies start having too much side effects. 



RE: Advanced Prostate Cancer

by ToddlerFather on Tue Dec 11, 2018 01:19 AM

Quote | Reply

It took a while for the effects to kick in. Target dosage of LDN is 4.5mg/day, but a slow ramp-up is recommended. Because of the frequency I went to the doctor that prescribed LDN, my ramp-up was of 8 months... during those 8 months, there was no effect for me. Tumor marker (Tg in thyroid cancer, similar to PSA in prostate cancer) was grewing exponentially... but a month after reaching the target dosage, it dropped 2/3 of the peak marker rate. After that, it's in decline, although a slow one that doctors prefer calling stabilization, for now. 

Compounded LDN in the US costs 50 cents a day, which is cheaper than most natural/holistic stuff, not only cheaper than chemo. 

You can discuss with your doctor how a ramp-up would look like for the specific case, but it's better to not rush it. That's why starting sooner also makes sense. 

RE: Advanced Prostate Cancer

by thomsor on Tue Dec 11, 2018 01:35 AM

Quote | Reply

Actually the theory behind what we are doing is to do exactly what it says because the balance is quite exact.  What you are doing is changing the DNA sequence of the cell to get it to stop producing aberrant cells.  The other theory is that microbes carry the cancer to the cells.  So part of what you are doing is killing the microbes that exist in the cells  There are no side effects from this process just money.  The Cellect power is $100.00 a week.  It's about $700.00 a month once you get the machine.  Another purchase I haven't gotten to yet is a zapper, another machine that kills microbes.  Oh, yes,you must check you iodine levels because iodine is deficient in our diets.  And yes, one hour of sunshine a day contrary to the popular medical nonsense that tells you to stay out of the sun.

This is an extension of Robert Barefoot therapy for cancer.

So, you are correcting any imbalance that exists in the body.  You can purchase the tapes for around $100.00 that explains all this.

Like I say,  this is a total body concept.  Once you get to what doctors would say is remission: you continue certain things that keep your body from going that way again.

My husband needed everything because he was a meat eater and a drinker.  A lot of things needed correcting.

People don't realize that some things we're being told are a bunch of junk - like eliminating salt from the body, staying out of the sun, etc.

It's good because it is a total therapy.  He has no pain which kind of surprises me because so many people with lower PSAs have pain.

There is also a place on the site where you can send in a urine test that will tell you the amount of cancer you are taking for $50.00 if you don't have a test like the PSA test.

To pay for this,  I've been getting offers to extend how long I have to pay for this and I've been using this because I'm also paying for the taxes on the rentals.  He cut out drinking, I cut out buying anything at all except for the stuff for him.  It's working for now.  But I'm also going to sell one of the rentals to catch up.

RE: Advanced Prostate Cancer

by Meetha on Wed Dec 12, 2018 08:10 AM

Quote | Reply
I admire your enthusiasm and experimentation. The heat therapy seem to be working for me too. The emerging pain in the groin and sitting bones seem to have been nipped in the bud. I soak in water over 40 degree C daily for 20 minutes. That's it. Only side effect is a brief spell of dizziness after emerging from hot tub. A rest of 10 minutes settles it. Otherwise, I have turned almost vegan since diagnosis. I am taking tomato soup too. I'm getting PSA tested tommorrow. With the just restarted pain in groin gone, I have no other symptoms, other than restricted urination. Let us see. I am looking at the new immunotherapy, which got Nobel Prize for Medicine this year, with a lot of hope. It promises to be commercialised as a cancer cure in ten years. If we hang on till then, we can to be cured, and not just manage the problem. All the best for your skull lesions. May be if you apply heat daily, the lesions vanish. Take care. Regards Meetha

RE: Advanced Prostate Cancer

by tomatoman on Sat Dec 15, 2018 01:11 AM

Quote | Reply

On Dec 12, 2018 8:10 AM Meetha wrote:

I admire your enthusiasm and experimentation. The heat therapy seem to be working for me too. The emerging pain in the groin and sitting bones seem to have been nipped in the bud. I soak in water over 40 degree C daily for 20 minutes. That's it. Only side effect is a brief spell of dizziness after emerging from hot tub. A rest of 10 minutes settles it. Otherwise, I have turned almost vegan since diagnosis. I am taking tomato soup too. I'm getting PSA tested tommorrow. With the just restarted pain in groin gone, I have no other symptoms, other than restricted urination. Let us see. I am looking at the new immunotherapy, which got Nobel Prize for Medicine this year, with a lot of hope. It promises to be commercialised as a cancer cure in ten years. If we hang on till then, we can to be cured, and not just manage the problem. All the best for your skull lesions. May be if you apply heat daily, the lesions vanish. Take care. Regards Meetha

Sounds good Meetha, similar to my own experience.  Ihavebeen doing hot shower on the skull treatment almost daily lately and it seems to have eliminated the headaches.  I do it about 15 seconds at 110F each morning. I can feel the heat getting down to the skull but not inside.  I use the hot plate at 130-110 on my left back every other day also.  Seems to eliminate that pain at least for a day or two.  Next PSA test for me is in early to mid February.

RE: Advanced Prostate Cancer

by Meetha on Mon Dec 17, 2018 03:00 PM

Quote | Reply
My PSA done two days ago showed that it has doubled from 34 to 62 in the last three months. All others tests reports were fine. . No bone pains. I wonder if a 15 days of heat therapy can cause this?Or whether my lesions are increasing? I have no pain and no other problem. The urologist has asked me to stop abirapro and tapered off the steroid as they are not helping in stopping the rise of PSA. He has called me after one month to decide what to do next. I am reverting to macrobiotic diet, which alone had helped me drop PSA earlier. Will get PSA done again after a month. One week before that, I'll stop heat therapy to nullify its effect on PSA rise. Till then fingers crossed. All the best.

RE: Advanced Prostate Cancer

by thomsor on Thu Dec 20, 2018 02:47 AM

Quote | Reply

I give you a report I just found.  My husband is going to get his PSA done next week.  He went from 33 to 19 the last time.  I reported the treatment.  Now I'm giving verification from another authority:  

Overview

Pulsed Electromagnetic Field Therapy (PEMF or PEMT) is a non-invasive, painless treatment which works by emitting a pulsating, varying intensity and frequency electromagnetic field, coming from a solenoid placed around the patient. Pulsed electromagnetic field therapy was approved by the FDA in 1979 specifically for the healing of nonunion fractures, which came after a Columbia University study that was encouraged by NASA, and has recently gained attention in the U.S (even appearing as a segment on the Dr. Oz Show). The value of pulsed electromagnetic field therapy has been shown to cover a wide range of conditions, with well documented trials carried out by hospitals, rheumatologists, physiotherapists, and neurologists. PEMF was widely used and with great success in the 19th and early 20th century. These primitive electromagnetic therapeutic devices were used by both medical doctors and non-allopathic health practitioners.

The research to date has shown that the mechanisms by which PEMF works are complicated and likely involve many pathways. In addition to increasing cell metabolism, perhaps PEMF’s greatest power is in its ability to ameliorate the effects of inflammation by decreasing inflammatory cytokines. it is also conceivable, as suggested by Gordon et al, that another important effect of PEMF is the ability of the magnetic fields to restore “equilibrium in ROS (free radical)/antioxidant chemistry. It is unequivocal that all chronic diseases result from a lack of homeostasis between free radicals and antioxidants. While both free radicals and antioxidants are normal and vital for processes such as cellular respiration and immunity, an imbalance could lead to cell and tissue death, DNA damage, and protein and fat degradation.

Pulsed Electromagnetic Field Therapy and Parkinson’s Disease

Magnetic therapy for Parkinson’s is nearly exclusively done in form of repetitive transcranial magnetic stimulation (rTMS). rTMS is in fact PEMF simply applied to the head and called repetitive transcranial magnetic stimulation.

A systematic review aimed to examine the efficacy of rTMS on improving physical function and motor signs over the short- and long-terms in people with PD; Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson's Disease: A Systematic Review and Meta-Analysis; Chung CL; Brain Stimul. 2016 Jul-Aug;9(4):475-87. Twenty-two trials comprising 555 people with PD were included in the review. The pooled evidence suggests that rTMS improves upper limb function in the short-term, walking performance and Unified Parkinson’s Disease rating Scale (UPDRS III) in the short- and long-terms in PD sufferers.

Pulsed Electromagnetic Field Therapy and Chronic Pain

A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain; Alex W Thomas, PhD; Pain Res Manag. 2007 Winter; 12(4): 249–258.

Exposure to a specific pulsed electromagnetic field (PEMF) has been shown to produce analgesic (antinociceptive) effects in many organisms. In a randomized, double-blind, sham-controlled clinical trial, patients with either chronic generalized pain from fibromyalgia (FM) or chronic localized musculoskeletal or inflammatory pain were exposed to a PEMF (400 μT) through a portable device fitted to their head during twice-daily 40 min treatments over seven days. The effect of this PEMF on pain reduction was recorded using a visual analogue scale. A differential effect of PEMF over sham treatment was noticed in patients with FM, which approached statistical significance (P=0.06) despite low numbers (n=17); this effect was not evident in those without FM (P=0.93; n=15). PEMF may be a novel, safe and effective therapeutic tool for use in at least certain subsets of patients with chronic, nonmalignant pain.

An open-label pilot study of pulsed electromagnetic field therapy in the treatment of failed back surgery syndrome pain; Wayne L Harper; Int Med Case Rep J. 2015; 8: 13–22 The primary objective of this open-label exploratory study was to investigate the analgesic effectiveness of pulsed electromagnetic field therapy administered twice daily over a 45-day period in 34 subjects (68% female) with persistent or recurrent pain following back surgery. Of the 30 per-protocol subjects who completed the study, 33% reported a clinically meaningful (≥30%) reduction in pain intensity (PI). A higher response rate (60%) was reported for subjects who had undergone discectomy prior to the trial compared to subjects who had undergone other types of surgical interventions (decompression or fusion) without discectomy. Improvements in PI were paralleled by improvements in secondary outcomes. Relative to baseline, responders reported an average 44% and 55% reduction in back PI and leg PI (respectively), and an average 13% improvement in Oswestry Disability Index scores. In the per-protocol population, 50% of responders and 12% of non-responders reported less analgesia consumption at the end of treatment versus baseline. Sixty-seven percent of per-protocol responders and 0% of non-responders reported clinically meaningful improvement in overall well-being on the Patient Global Impression of Change scale.

Pulsed Electromagnetic Field Therapy and Multiple Sclerosis

Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial; Lappin MS; Altern Ther Health Med. 2003 Jul-Aug;9(4):38-48. This study is a follow-up to a placebo controlled pilot study in which multiple sclerosis (MS) patients exposed to weak, extremely low frequency pulsed electromagnetic fields showed significant improvements on a composite symptom measure. This study was a multi-site, double-blind, placebo controlled, crossover trial involving 117 patients with MS. Each subject received 4 weeks of the active and placebo treatments separated by a 2-week washout period. Paired t-tests were used to assess treatment differences in the 117 subjects (81% of the initial sample) who completed both treatment sessions. Improvements in fatigue and overall quality of life were significantly greater on the active device.

Pulsed Electromagnetic Field Therapy and Dementia

Cognitive functioning after repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia: a pilot study of seven patients; Rektorova; J Neurol Sci. 2005 Mar 15;229-230:157-61 This study aimed to examine whether one session of high frequency repetitive transcranial magnetic stimulation (rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) would induce any measurable cognitive changes in patients with cerebrovascular disease and mild cognitive deficits. Seven patients with cerebrovascular disease and mild executive dysfunction entered the randomized, controlled, blinded study with a crossover design. rTMS was applied either over the left DLPFC (an active stimulation site) or over the left motor cortex (MC; a control stimulation site) in one session. Each patient participated in both stimulation sessions (days 1 and 4) and the order of stimulation sites (DLPFC or MC) was randomized. A short battery of neuropsychological tests was performed by a blinded psychologist prior to and after each rTMS session. Psychomotor speed, executive function, and memory were evaluated. Results: mild but significant stimulation site-specific effect of rTMS was observed in the Stroop interference results (i.e. improvement) after the stimulation of DLPFC in comparison with the baseline scores (Wilcoxon, Z=-2.03, p=0.04). Patients improved in the digit symbols subtest of the Wechsler adult intelligence scale-revised after both rTMS sessions regardless of the stimulation site.

Alzheimer’s disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields; Sandyk R; Int J Neurosci. 1994 Jun;76(3-4):185-225. The author had previously reported that external application of electromagnetic fields (EMF) of extremely low intensity (in the picotesla range) and of low frequency (in the range of 5Hz-8Hz) improved visual memory and visuoperceptive functions in patients with Parkinson's disease. Since a subgroup of Parkinsonian patients, specifically those with dementia, have coexisting pathological and clinical features of AD, the author investigated in two AD patients the effects of these extremely weak EMF on visual memory and visuoconstructive performance. The Rey-Osterrieth Complex Figure Test as well as sequential drawings from memory of a house, a bicycle, and a man were employed to evaluate the effects of EMF on visual memory and visuoconstructive functions, respectively. In both patients treatment with EMF resulted in a dramatic improvement in visual memory and enhancement of visuoconstructive performance which was associated clinically with improvement in other cognitive functions such as short term memory, calculations, spatial orientation, judgement and reasoning as well as level of energy, social interactions, and mood. The report demonstrates, for the first time, that specific cognitive symptoms of AD are improved by treatment with EMF of a specific intensity and frequency. The rapid improvement in cognitive functions in response to EMF suggests that some of the mental deficits of AD are reversible being caused by a functional (i.e., synaptic transmission) rather than a structural (i.e., neuritic plaques) disruption of neuronal communication in the central nervous system.

Pulsed Electromagnetic Field Therapy in Cancer

Several mechanisms of PEMF therapy have been elucidated with regards to cancer. These studies have shown that PEMF therapy may exert proliferative inhibition and mitotic spindle disruption, block the development of neovascularization (blood supply) required for tumor growth and exacerbate an inherent or induced genetic instability by reducing the stringency of the late-cycle (G2) checkpoint. PEMF therapy also modulates gene expression and protein synthesis, interacting with specific DNA sequences within gene promoter regions. PEMFs have also an immunomodulatory effect, as supported by in vivo evidence showing an increase in tumor necrosis factor alpha levels that induce an anti-tumoral response.

Changes in blood pressure, skin electrical resistance, and pulse amplitude in 163 oncology patients exposed to tumor-specific PEMF frequencies have also been reported suggesting that PEMF therapy does not only target neoplastic cells, but may also have systemic effects. However, long-term PEMF treatment has been shown to be non-toxic, and employs 100,000 times lower frequencies as compared with radiofrequency ablation that is also employed for treatment of many cancers.

While chemotherapy is not specific to cancer cells and targets all rapidly dividing cells, PEMFs exert selective cytotoxic effect on neoplastic cells making this therapy a highly promising strategy.

In Vivo Studies

Several studies investigated the antineoplastic effect of PEMFs using widely employed animal models of several types of cancer, including breast cancer, hepatocellular carcinoma (HCC), and melanoma.

PEMF therapy effectiveness in mouse models of breast cancer; Mice were divided into four groups (n = 3 each). Group 1, 2, and 3 were exposed to PEMF therapy (1 Hz, 100 mT) daily for 60, 180, or 360 min, respectively, for 4 weeks, while group 4 did not receive PEMF therapy and was used as control. All mice were monitored for tumor growth by body bioluminescence imaging once every 2 to 4 days for 4 weeks. Then, all the mice were sacrificed and skin, liver, lung, and spleen samples were collected for histopathologic analysis. Mice exposed to PEMFs for 60 and 180 min daily showed a 30% and 70% breast tumor reduction, respectively, at week 4. Mice exposed to PEMF for 360 min daily, showed a suppression of tumor growth at week 4. In summary, this study shows that the time of PEMF exposure is critical to determine its effectiveness. Mice exposed for longer duration (360 min daily for 4 weeks) showed a significant reduction in tumor size, due probably to the inhibition of angiogenesis that may suppress the formation of blood vessels in tumor tissues, reducing the tumor growth.

Human Clinical Studies

The first study utilizing PEMF therapy was conducted by Barbault and coworkers who hypothesized that a combination of defined tumor-specific frequencies, may display therapeutic effectiveness for localized treatment of tumors. They identified a total of 1524 tumor-specific frequencies, ranging from 0.1 to 114 kHz, consisting in the measurement of variations in skin electrical resistance, pulse amplitude, and blood pressure in 163 patients affected by different types of cancer including brain tumors, colorectal cancer, hepatocellular carcinoma, pancreatic, colorectal, ovarian, breast, prostate, lung, thyroid, and bladder cancer and exposed to the radiofrequency system.

Self-administered PEMF therapy for 60 min, three times a day, for an average of 278.4 months was offered to only 28 patients with advanced cancer: 7 breast cancer, 5 ovarian cancer, 3 pancreatic cancer, 2 colorectal cancer, 2 prostate cancer, 1 glioblastoma multiforme, 1 hepatocellular carcinoma, 1 mesothelioma, 1 neuroendocrine tumor, 1 non-small-cell lung cancer, 1 oligodendroglioma, 1 small-cell lung cancer, 1 sarcoma, and 1 thyroid tumor. None of the patients who received PEMF therapy reported any side effects; four patients presented stable disease for 3 years (thyroid cancer with biopsy-proven lung metastases), 6 months (mesothelioma metastatic to the abdomen), 5 months (non-small-cell lung cancer), and 4 months (pancreatic cancer with biopsy-proven liver metastases), respectively.

The feasibility of PEMF therapy for treatment of hepatocellular carcinoma (HCC) has also been investigated in a single-group, open-label, phase I/II clinical study. Forty-one patients with advanced HCC received very low levels of PEMFs modulated at HCC-specific frequencies (100 Hz–21 kHz) and received three-daily 60 min outpatient treatments. No adverse reactions were observed during PEMF treatment. Five patients reported complete disappearance and two patients reported decrease in pain shortly after beginning of treatment. Four patients showed a partial response to treatment, while 16 patients (39%) had stable disease for more than 12 weeks. This study shows that PEMF therapy provides a safe and well-tolerated treatment, as well as evidence of antineoplastic effects in patients with HCC.

PEMF therapy is more commonly used in Europe to treat many ailments, including cancer. Although only two clinical studies have used PEMF therapy for cancer treatment, these studies show that PEMF therapy is safe and promising compared to other available cancer therapies. PEMFs could be used not only as primary therapy but also in combination with other common antineoplastic therapies. Given that new portable and affordable PEMF devices are increasingly available on the market, future controlled clinical studies are expected to further determine the potential of PEMF therapy in conventional oncology.

RE: Advanced Prostate Cancer

by thomsor on Thu Dec 20, 2018 02:53 AM

Quote | Reply

A recent article I found confirms that this type of treatment works.  Combined with other therapy, you can look for a cure but only if you do the program.  Please be advised that they only use half-dead patients when they are talking about advanced cases.  And if you are talking about radiation, you may not be able to convert the cells back to norma.  Like I said, the first PSA test my husband went from 33 to 19.  Do not publish this information because the only way you can get a machine at this time is to say it is experimental although they are selling it to horses without a problem.  Glad the other stuff works for you as these machines are not cheap.  But it was approved for depression and the doctors are getting $300.00 to $500.00 a 20 minute therapy session 3 to 5 times a week.

If you try it, only buy the Rife machine.

Overview

Pulsed Electromagnetic Field Therapy (PEMF or PEMT) is a non-invasive, painless treatment which works by emitting a pulsating, varying intensity and frequency electromagnetic field, coming from a solenoid placed around the patient. Pulsed electromagnetic field therapy was approved by the FDA in 1979 specifically for the healing of nonunion fractures, which came after a Columbia University study that was encouraged by NASA, and has recently gained attention in the U.S (even appearing as a segment on the Dr. Oz Show). The value of pulsed electromagnetic field therapy has been shown to cover a wide range of conditions, with well documented trials carried out by hospitals, rheumatologists, physiotherapists, and neurologists. PEMF was widely used and with great success in the 19th and early 20th century. These primitive electromagnetic therapeutic devices were used by both medical doctors and non-allopathic health practitioners.

The research to date has shown that the mechanisms by which PEMF works are complicated and likely involve many pathways. In addition to increasing cell metabolism, perhaps PEMF’s greatest power is in its ability to ameliorate the effects of inflammation by decreasing inflammatory cytokines. it is also conceivable, as suggested by Gordon et al, that another important effect of PEMF is the ability of the magnetic fields to restore “equilibrium in ROS (free radical)/antioxidant chemistry. It is unequivocal that all chronic diseases result from a lack of homeostasis between free radicals and antioxidants. While both free radicals and antioxidants are normal and vital for processes such as cellular respiration and immunity, an imbalance could lead to cell and tissue death, DNA damage, and protein and fat degradation.

Pulsed Electromagnetic Field Therapy and Parkinson’s Disease

Magnetic therapy for Parkinson’s is nearly exclusively done in form of repetitive transcranial magnetic stimulation (rTMS). rTMS is in fact PEMF simply applied to the head and called repetitive transcranial magnetic stimulation.

A systematic review aimed to examine the efficacy of rTMS on improving physical function and motor signs over the short- and long-terms in people with PD; Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson's Disease: A Systematic Review and Meta-Analysis; Chung CL; Brain Stimul. 2016 Jul-Aug;9(4):475-87. Twenty-two trials comprising 555 people with PD were included in the review. The pooled evidence suggests that rTMS improves upper limb function in the short-term, walking performance and Unified Parkinson’s Disease rating Scale (UPDRS III) in the short- and long-terms in PD sufferers.

Pulsed Electromagnetic Field Therapy and Chronic Pain

A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain; Alex W Thomas, PhD; Pain Res Manag. 2007 Winter; 12(4): 249–258.

Exposure to a specific pulsed electromagnetic field (PEMF) has been shown to produce analgesic (antinociceptive) effects in many organisms. In a randomized, double-blind, sham-controlled clinical trial, patients with either chronic generalized pain from fibromyalgia (FM) or chronic localized musculoskeletal or inflammatory pain were exposed to a PEMF (400 μT) through a portable device fitted to their head during twice-daily 40 min treatments over seven days. The effect of this PEMF on pain reduction was recorded using a visual analogue scale. A differential effect of PEMF over sham treatment was noticed in patients with FM, which approached statistical significance (P=0.06) despite low numbers (n=17); this effect was not evident in those without FM (P=0.93; n=15). PEMF may be a novel, safe and effective therapeutic tool for use in at least certain subsets of patients with chronic, nonmalignant pain.

An open-label pilot study of pulsed electromagnetic field therapy in the treatment of failed back surgery syndrome pain; Wayne L Harper; Int Med Case Rep J. 2015; 8: 13–22 The primary objective of this open-label exploratory study was to investigate the analgesic effectiveness of pulsed electromagnetic field therapy administered twice daily over a 45-day period in 34 subjects (68% female) with persistent or recurrent pain following back surgery. Of the 30 per-protocol subjects who completed the study, 33% reported a clinically meaningful (≥30%) reduction in pain intensity (PI). A higher response rate (60%) was reported for subjects who had undergone discectomy prior to the trial compared to subjects who had undergone other types of surgical interventions (decompression or fusion) without discectomy. Improvements in PI were paralleled by improvements in secondary outcomes. Relative to baseline, responders reported an average 44% and 55% reduction in back PI and leg PI (respectively), and an average 13% improvement in Oswestry Disability Index scores. In the per-protocol population, 50% of responders and 12% of non-responders reported less analgesia consumption at the end of treatment versus baseline. Sixty-seven percent of per-protocol responders and 0% of non-responders reported clinically meaningful improvement in overall well-being on the Patient Global Impression of Change scale.

Pulsed Electromagnetic Field Therapy and Multiple Sclerosis

Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial; Lappin MS; Altern Ther Health Med. 2003 Jul-Aug;9(4):38-48. This study is a follow-up to a placebo controlled pilot study in which multiple sclerosis (MS) patients exposed to weak, extremely low frequency pulsed electromagnetic fields showed significant improvements on a composite symptom measure. This study was a multi-site, double-blind, placebo controlled, crossover trial involving 117 patients with MS. Each subject received 4 weeks of the active and placebo treatments separated by a 2-week washout period. Paired t-tests were used to assess treatment differences in the 117 subjects (81% of the initial sample) who completed both treatment sessions. Improvements in fatigue and overall quality of life were significantly greater on the active device.

Pulsed Electromagnetic Field Therapy and Dementia

Cognitive functioning after repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia: a pilot study of seven patients; Rektorova; J Neurol Sci. 2005 Mar 15;229-230:157-61 This study aimed to examine whether one session of high frequency repetitive transcranial magnetic stimulation (rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) would induce any measurable cognitive changes in patients with cerebrovascular disease and mild cognitive deficits. Seven patients with cerebrovascular disease and mild executive dysfunction entered the randomized, controlled, blinded study with a crossover design. rTMS was applied either over the left DLPFC (an active stimulation site) or over the left motor cortex (MC; a control stimulation site) in one session. Each patient participated in both stimulation sessions (days 1 and 4) and the order of stimulation sites (DLPFC or MC) was randomized. A short battery of neuropsychological tests was performed by a blinded psychologist prior to and after each rTMS session. Psychomotor speed, executive function, and memory were evaluated. Results: mild but significant stimulation site-specific effect of rTMS was observed in the Stroop interference results (i.e. improvement) after the stimulation of DLPFC in comparison with the baseline scores (Wilcoxon, Z=-2.03, p=0.04). Patients improved in the digit symbols subtest of the Wechsler adult intelligence scale-revised after both rTMS sessions regardless of the stimulation site.

Alzheimer’s disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields; Sandyk R; Int J Neurosci. 1994 Jun;76(3-4):185-225. The author had previously reported that external application of electromagnetic fields (EMF) of extremely low intensity (in the picotesla range) and of low frequency (in the range of 5Hz-8Hz) improved visual memory and visuoperceptive functions in patients with Parkinson's disease. Since a subgroup of Parkinsonian patients, specifically those with dementia, have coexisting pathological and clinical features of AD, the author investigated in two AD patients the effects of these extremely weak EMF on visual memory and visuoconstructive performance. The Rey-Osterrieth Complex Figure Test as well as sequential drawings from memory of a house, a bicycle, and a man were employed to evaluate the effects of EMF on visual memory and visuoconstructive functions, respectively. In both patients treatment with EMF resulted in a dramatic improvement in visual memory and enhancement of visuoconstructive performance which was associated clinically with improvement in other cognitive functions such as short term memory, calculations, spatial orientation, judgement and reasoning as well as level of energy, social interactions, and mood. The report demonstrates, for the first time, that specific cognitive symptoms of AD are improved by treatment with EMF of a specific intensity and frequency. The rapid improvement in cognitive functions in response to EMF suggests that some of the mental deficits of AD are reversible being caused by a functional (i.e., synaptic transmission) rather than a structural (i.e., neuritic plaques) disruption of neuronal communication in the central nervous system.

Pulsed Electromagnetic Field Therapy in Cancer

Several mechanisms of PEMF therapy have been elucidated with regards to cancer. These studies have shown that PEMF therapy may exert proliferative inhibition and mitotic spindle disruption, block the development of neovascularization (blood supply) required for tumor growth and exacerbate an inherent or induced genetic instability by reducing the stringency of the late-cycle (G2) checkpoint. PEMF therapy also modulates gene expression and protein synthesis, interacting with specific DNA sequences within gene promoter regions. PEMFs have also an immunomodulatory effect, as supported by in vivo evidence showing an increase in tumor necrosis factor alpha levels that induce an anti-tumoral response.

Changes in blood pressure, skin electrical resistance, and pulse amplitude in 163 oncology patients exposed to tumor-specific PEMF frequencies have also been reported suggesting that PEMF therapy does not only target neoplastic cells, but may also have systemic effects. However, long-term PEMF treatment has been shown to be non-toxic, and employs 100,000 times lower frequencies as compared with radiofrequency ablation that is also employed for treatment of many cancers.

While chemotherapy is not specific to cancer cells and targets all rapidly dividing cells, PEMFs exert selective cytotoxic effect on neoplastic cells making this therapy a highly promising strategy.

In Vivo Studies

Several studies investigated the antineoplastic effect of PEMFs using widely employed animal models of several types of cancer, including breast cancer, hepatocellular carcinoma (HCC), and melanoma.

PEMF therapy effectiveness in mouse models of breast cancer; Mice were divided into four groups (n = 3 each). Group 1, 2, and 3 were exposed to PEMF therapy (1 Hz, 100 mT) daily for 60, 180, or 360 min, respectively, for 4 weeks, while group 4 did not receive PEMF therapy and was used as control. All mice were monitored for tumor growth by body bioluminescence imaging once every 2 to 4 days for 4 weeks. Then, all the mice were sacrificed and skin, liver, lung, and spleen samples were collected for histopathologic analysis. Mice exposed to PEMFs for 60 and 180 min daily showed a 30% and 70% breast tumor reduction, respectively, at week 4. Mice exposed to PEMF for 360 min daily, showed a suppression of tumor growth at week 4. In summary, this study shows that the time of PEMF exposure is critical to determine its effectiveness. Mice exposed for longer duration (360 min daily for 4 weeks) showed a significant reduction in tumor size, due probably to the inhibition of angiogenesis that may suppress the formation of blood vessels in tumor tissues, reducing the tumor growth.

Human Clinical Studies

The first study utilizing PEMF therapy was conducted by Barbault and coworkers who hypothesized that a combination of defined tumor-specific frequencies, may display therapeutic effectiveness for localized treatment of tumors. They identified a total of 1524 tumor-specific frequencies, ranging from 0.1 to 114 kHz, consisting in the measurement of variations in skin electrical resistance, pulse amplitude, and blood pressure in 163 patients affected by different types of cancer including brain tumors, colorectal cancer, hepatocellular carcinoma, pancreatic, colorectal, ovarian, breast, prostate, lung, thyroid, and bladder cancer and exposed to the radiofrequency system.

Self-administered PEMF therapy for 60 min, three times a day, for an average of 278.4 months was offered to only 28 patients with advanced cancer: 7 breast cancer, 5 ovarian cancer, 3 pancreatic cancer, 2 colorectal cancer, 2 prostate cancer, 1 glioblastoma multiforme, 1 hepatocellular carcinoma, 1 mesothelioma, 1 neuroendocrine tumor, 1 non-small-cell lung cancer, 1 oligodendroglioma, 1 small-cell lung cancer, 1 sarcoma, and 1 thyroid tumor. None of the patients who received PEMF therapy reported any side effects; four patients presented stable disease for 3 years (thyroid cancer with biopsy-proven lung metastases), 6 months (mesothelioma metastatic to the abdomen), 5 months (non-small-cell lung cancer), and 4 months (pancreatic cancer with biopsy-proven liver metastases), respectively.

The feasibility of PEMF therapy for treatment of hepatocellular carcinoma (HCC) has also been investigated in a single-group, open-label, phase I/II clinical study. Forty-one patients with advanced HCC received very low levels of PEMFs modulated at HCC-specific frequencies (100 Hz–21 kHz) and received three-daily 60 min outpatient treatments. No adverse reactions were observed during PEMF treatment. Five patients reported complete disappearance and two patients reported decrease in pain shortly after beginning of treatment. Four patients showed a partial response to treatment, while 16 patients (39%) had stable disease for more than 12 weeks. This study shows that PEMF therapy provides a safe and well-tolerated treatment, as well as evidence of antineoplastic effects in patients with HCC.

PEMF therapy is more commonly used in Europe to treat many ailments, including cancer. Although only two clinical studies have used PEMF therapy for cancer treatment, these studies show that PEMF therapy is safe and promising compared to other available cancer therapies. PEMFs could be used not only as primary therapy but also in combination with other common antineoplastic therapies. Given that new portable and affordable PEMF devices are increasingly available on the market, future controlled clinical studies are expected to further determine the potential of PEMF therapy in conventional oncology.

RE: Advanced Prostate Cancer

by tomatoman on Wed Dec 26, 2018 04:30 PM

Quote | Reply

On Dec 17, 2018 3:00 PM Meetha wrote:

My PSA done two days ago showed that it has doubled from 34 to 62 in the last three months. All others tests reports were fine. . No bone pains. I wonder if a 15 days of heat therapy can cause this?Or whether my lesions are increasing? I have no pain and no other problem. The urologist has asked me to stop abirapro and tapered off the steroid as they are not helping in stopping the rise of PSA. He has called me after one month to decide what to do next. I am reverting to macrobiotic diet, which alone had helped me drop PSA earlier. Will get PSA done again after a month. One week before that, I'll stop heat therapy to nullify its effect on PSA rise. Till then fingers crossed. All the best.

Meetha

It is possible that the heat therapy actually causes a rise in PSA and therefore a faulty reading.  And in fact the articles and books I read suggest that PSA would decline only after an extended period like one or two months after treatment.

If you look at the causes of PSA rise you will see  that any kind of stimulation of the prostate gland or in the case of stage 4 prostate cancer, the migrated tumors, will cause a rise in the level of PSA  in the blood.  Even a DRE but more significantly radiation treatment can cause a rise in PSA.  I think of heat therapy as a form of radiation therapy.

Therefore it stands to reason that heat therapy could cause a faulty reading.  The problem then is that if you stop the therapy for an extensive time then theoretically the PSA should diminish over time but at the same time, if the tumors remain and grow, they will have the effect of causing the PSA to rise at the same time. So what you get is a PSA reading that goes up even when the tumor mass is shrinking, and it takes a long time with consistent application for heat therapy to reduce the PSA.  

I have tried stopping the therapy as much as ten days prior to the PSA test but my PSA continued to rise.  In the last test I stopped therapy for just five days.  The rate of rise in my case was a doubling in six months.  In your case you seem to be doubling faster, in about three months.  I suspect that this means that your tumor mass is larger than mine.  My PSA last rose from 11.6 to 12.8 in three months (Aug-Oct. '18).  

I think what is happening is that the heat therapy slows the tumor growth, possilby even killing some of the cancer cells, but not all.  Then in the period following the therapy, the tumors then grow.  They are constantly growing but they are reduced in their rate of growth during heat treatment because the mass decreases.

I am thinking that what is necessary to shrink the tumors is a combination of the heat as well as another therapy, e.g. a high lycopene intake, (or hormone therapy).  Since the lycopene intake only affects the tumors for a short time after consumption, it is necessary to keep constantly elevating the lycopene level by consuming lycopenes every four hours approximately.  This I believe is because the lycopenes are only absorbed by a small portion of the intestine, so as the lycopene-rich food passes through that portion of the intestine, it causes a temporary high level in the blood.

The macrobiotic diet probably reduces the tumor growth rate by starving the cells, but I imagine all healthy cells are likewise starved and therefore normal healthy cell replacement would slow also.

Those are my thoughts lately.  Hope they help. Happy Holidays and best wishes in the new year. Mike

RE: Advanced Prostate Cancer

by tomatoman on Fri Dec 28, 2018 01:55 PM

Quote | Reply

I forgot to point out in the previous post that lycopene intake alone needs to be combined with two things: first, add a little olive or vegetable oil to the lycopene rich food such as tomato sauce or paste, v8 juice, or catsup, and second, add a little capsaicin such as hot sauce, to the food.  This will help the lycopene absorption in the blood (oil) and  effectiveness in aptosis (capsaicin)...according to what I have read.

40 Posts | Page(s): Prev 12 3 4 
Subscribe to this message board discussion

We care about your feedback. Let us know how we can improve your CancerCompass experience.